Development of Tumor Organoids from Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions

Not Applicable

Not yet recruiting

• Conditions: Undifferentiated Carcinoma

• Registration Number: NCT06612827
• Lead Sponsor: Centre Francois Baclesse

Brief Summary

The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-09-23
• Study First Submitted QC: 2024-09-23
• Study First Posted: 2024-09-25
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-04
• Last Update Posted: 2024-11-07
• Study Start: 2024-12-15
• Primary Completion: 2027-12-15
• Study Completion: 2031-12-15

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
• Patient with indication for 1st-line treatment at the time of inclusion.
• Patient with life expectancy greater than 3 months
• Patient of legal age
• Patient affiliated to a social security scheme
• Signature of informed consent prior to any specific study procedure

Exclusion Criteria

• Persons deprived of their liberty or under guardianship (including curatorship)
• Pregnant or breast-feeding patient

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Rate of establishment of exploitable tumor organoids	through study completion, an average of 3 years	Rate of establishment usable tumor organoids for predictive tests of response to treatment.

Trial Locations

Locations (1)

Centre François Baclesse; 🇫🇷 Caen, France